Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review

Abstract

Background Cognitive impairment is a core feature of depression and has a negative effect on a person's functioning, in psychosocial and interpersonal areas, and on workforce performance. Cognitive impairment often persists, even with the remittance of mood symptoms. One potential way of improving treatment of cognitive impairment would be to identify variables that predict cognitive change in patients with depression. Aims To systematically examine findings from studies that investigate baseline variables and how they predict, or correlate with, cognitive change in mood disorders, and to examine methodological issues from these studies. Method Studies that directly measured associations between at least one baseline variable and change in cognitive outcome in patients with current major depressive episode were identified using PubMed and Web of Science databases. Narrative review technique was used because of the heterogeneity of patient samples, outcome measures and study procedures. The review was registered on PROSPERO with registration number CRD42020150975. Results Twenty-four studies met the inclusion criteria. Evidence from the present review for prediction of cognitive change from baseline variables was limited for demographic factors, with some preliminary evidence for depression, cognitive and biological factors. Identification of patterns across studies was difficult because of methodological variability across studies. Conclusions Findings from the present review suggest there may be some baseline variables that are useful in predicting cognitive change in mood disorders. This is an area warranting further research focus.

Psychological factors and coping strategies in pregnancies complicated by hypertension: A cluster-analytic approach

“…When only patients with impaired cognitive performance (psychomotor speed) at baseline were included in the analysis, early improvement of depressive symptoms by antidepressant treatment was associated with a greater improvement in cognitive performance at month 6. These results are in line with previous findings that the treatment effect is more pronounced in patients with cognitive decline at treatment initiation than those without cognitive impairment (Barczyk et al, 2020;Groves et al, 2018;Murrough et al, 2015). Thus, early evaluation of depressive symptoms may be useful for predicting cognitive performance, particularly in patients who elicit cognitive impairment at the start of antidepressant treatment.…”

Systematic review of the effects of evidence-based psychotherapies on neurocognitive functioning in mood disorders

“…It is noteworthy that the patient group was enriched for executive deficit, thereby addressing the issue of dilution of study findings by inclusion of cognitively unimpaired individuals. Indeed, there is evidence that baseline deficit is predictive of cognitive change with treatment (Barczyk et al, 2020;Miskowiak et al, 2016). However, it is also important to note that this was an isolated finding.…”

Cognition in mood disorders

“…In an attempt to understand what predicts improvement in cognitive function in the treatment of major depressive episodes, Barczyk et al 10 (this series) examined studies that measured cognitive function at baseline and at follow-up, after treatment of an episode of major depression. Once again, age was a significant issue in the review, with studies being best understood by a split into younger and older patients.…”

“…In late-life depression and bipolar disorder, understanding cognitive function is complicated by the relationship between the mood disorders and dementia, with episodes of mood disorder being associated with risk of dementia. 19 Barczyk et al 10 (this series), in their review of factors that predict cognitive change, note that in some longer-term studies in late-life depression, cognitive change is predominantly negative. These studies examine what predicts a decline, finding that, for example, the number of deep white matter lesions appears to be a significant factor.…”